View Older Stories View More Recent Stories
-
Compass Therapeutics (CMPX) PT Lowered to $6 at Stifel
-
H.C. Wainwright on Compass Therapeutics (CMPX): 'we do believe the probability of a path forward is meaningfully higher than the market reaction observed'
-
Leerink on Compass Therapeutics (CMPX): 'there are multiple sources of long-term upside'
-
Stifel on Compass Therapeutics (CMPX): 'Path Forward Complicated by FDA’s “Imply-No-Harm” Mandate'
-
Compass Therapeutics stock plunges on trial data concerns, William Blair comments
-
William Blair on Compass Therapeutics (CMPX) 75% Drop: 'This will raise questions on the approvability of this dataset'
-
Increasing unusual option volume: CMPX IVZ BKLN UTHR KIE ORBS BMEA SGHC
-
Increasing unusual option volume: CMPX ALLO GSAT CTRA CORN IDYA
-
Compass Therapeutics (CMPX) Reiterated at Buy by Stifel Ahead of April Disclosure
-
Cantor Fitzgerald Reiterates Overweight Rating on Compass Therapeutics (CMPX) Ahead of PFS/OS Readout
-
Compass Therapeutics (CMPX) Reiterated at Market Outperform by Citizens
-
Compass Therapeutics, Inc. (CMPX) Tops Q4 EPS by 1c
-
Compass Therapeutics (CMPX) PT Raised to $9 at Jefferies
-
William Blair Reiterates Outperform Rating on Compass Therapeutics (CMPX)
-
Raymond James Reiterates Outperform Rating on Compass Therapeutics (CMPX) following Q4 results
-
Craig-Hallum Starts Compass Therapeutics (CMPX) at Buy
-
Compass Therapeutics (CMPX) PT Raised to $13 at Canaccord Genuity
-
Compass Therapeutics (CMPX) Reiterated at Market Outperform by Citizens
-
Stifel Reiterates Buy Rating on Compass Therapeutics (CMPX)
-
Raymond James Reiterates Outperform Rating on Compass Therapeutics (CMPX)
-
Compass Therapeutics reports $209 million cash, appoints new executives
-
Compass Therapeutics names new commercial and medical officers
-
William Blair Starts Compass Therapeutics (CMPX) at Outperform
-
Compass Therapeutics, Inc (CMPX) files $400M mixed shelf
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
Cantor Fitzgerald Starts Compass Therapeutics (CMPX) at Overweight
-
Canaccord Genuity Starts Compass Therapeutics (CMPX) at Buy
-
Citizens Starts Compass Therapeutics (CMPX) at Market Outperform
-
Compass Therapeutics presents preclinical data for cancer bispecific antibody
-
Piper Sandler on Compass Therapeutics (CMPX): 'Early '8371 Responses Are Super Interesting'
-
Compass Therapeutics (CMPX) PT Raised to $12 at Guggenheim
-
Compass Therapeutics (CMPX) PT Raised to $7 at Leerink Partners
-
Raymond James Reiterates Outperform Rating on Compass Therapeutics (CMPX)
-
Compass Therapeutics, Inc. (CMPX) Misses Q2 EPS by 2c
-
Stifel Reiterates Buy Rating on Compass Therapeutics (CMPX)
-
Raymond James Resumes Compass Therapeutics (CMPX) at Outperform
-
Compass Therapeutics, Inc. (CMPX) Misses Q1 EPS by 1c
-
H.C. Wainwright Reiterates Buy Rating on Compass Therapeutics (CMPX)
-
H.C. Wainwright Reiterates Buy Rating on Compass Therapeutics (CMPX)
-
Compass Therapeutics (CMPX) Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer
-
Leerink Partners Upgrades Compass Therapeutics (CMPX) to Outperform
-
Compass Therapeutics, Inc (CMPX) Reports CTX-009 Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study
-
Compass Therapeutics (CMPX) to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer
-
Stifel Reiterates Buy Rating on Compass Therapeutics (CMPX)
-
Compass Therapeutics, Inc. (CMPX) Misses Q4 EPS by 1c
-
Piper Sandler Starts Compass Therapeutics (CMPX) at Overweight
-
Compass Therapeutics (CMPX) Provides Corporate Update and Announces Advancement of a New Drug Candidate
-
Compass Therapeutics (CMPX) Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
-
Compass Therapeutics, Inc. (CMPX) Tops Q3 EPS by 3c
-
Ladenburg Thalmann Upgrades Compass Therapeutics (CMPX) to Buy

